Literature DB >> 25930714

Disruption of melatonin circadian rhythm production is related to multiple sclerosis severity: A preliminary study.

Alfredo Damasceno1, Adriel Santos Moraes2, Alessandro Farias2, Benito Pereira Damasceno3, Leonilda Maria Barbosa dos Santos2, Fernando Cendes3.   

Abstract

Sunlight can influence the immune system independently of vitamin D, such as through melatonin production in the pineal gland. Inflammatory disorders can suppress nocturnal melatonin production, but only a few studies have investigated melatonin status in multiple sclerosis (MS). We aimed to study melatonin production in association with clinical and immunological data in MS patients. Eleven treated relapsing-remitting MS (RRMS) patients and eight controls underwent neurological examination and were assessed for fatigue severity and depressive symptoms. Inflammatory cytokines were analyzed in blood samples and concentration of 6-sulfatoxymelatonin (6-SMT) was determined in 24h urine. Patients with an abnormal proportion of overnight 6-SMT (n=8, 72.7%) had higher disability and fatigue severity (p<0.05). Overnight 6-SMT was inversely related with fatigue severity (p=0.016), number of relapses in the previous 12 months (p=0.010) and EDSS scores (p=0.049). In conclusion, disruption of melatonin circadian rhythm production is frequent among RRMS patients and seemingly related to higher disability and fatigue scores. Future studies with larger sample size are necessary to establish melatonin status as a biomarker of disease severity in MS.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  6-Sulfatoxymelatonin; Biomarker; Melatonin; Multiple sclerosis

Mesh:

Substances:

Year:  2015        PMID: 25930714     DOI: 10.1016/j.jns.2015.03.040

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  14 in total

1.  Clinical relevance of circadian melatonin release in relapsing-remitting multiple sclerosis.

Authors:  Simone Kern; Michael Geiger; Madlen Paucke; Alina Kästner; Katja Akgün; Tjalf Ziemssen
Journal:  J Mol Med (Berl)       Date:  2019-08-30       Impact factor: 4.599

Review 2.  The role of melatonin in Multiple Sclerosis.

Authors:  Charalampos Skarlis; Maria Anagnostouli
Journal:  Neurol Sci       Date:  2019-12-16       Impact factor: 3.307

Review 3.  Potential Circadian Rhythms in Oligodendrocytes? Working Together Through Time.

Authors:  Christopher S Colwell; Cristina A Ghiani
Journal:  Neurochem Res       Date:  2019-03-25       Impact factor: 3.996

4.  Neuroprotective Effects of Melatonin on Experimental Allergic Encephalomyelitis Mice Via Anti-Oxidative Stress Activity.

Authors:  Ting Long; Yuan Yang; Ling Peng; Zuoxiao Li
Journal:  J Mol Neurosci       Date:  2018-02-15       Impact factor: 3.444

5.  Rotating night shift work and risk of multiple sclerosis in the Nurses' Health Studies.

Authors:  Kyriaki Papantoniou; Jennifer Massa; Elizabeth Devore; Kassandra L Munger; Tanuja Chitnis; Alberto Ascherio; Eva S Schernhammer
Journal:  Occup Environ Med       Date:  2019-08-12       Impact factor: 4.402

6.  Effect of Treatment with Thyme Extract on Urinary Levels of Melatonin in an Experimental Autoimmune Encephalomyelitis Mouse Model.

Authors:  Merat Mahmoodi; Farnaz Sedghy; Abdollah Jafarzadeh
Journal:  Rep Biochem Mol Biol       Date:  2020-01

7.  Mobile Technology Use by People Experiencing Multiple Sclerosis Fatigue: Survey Methodology.

Authors:  Kirsten Van Kessel; Duncan R Babbage; Nicholas Reay; Warren M Miner-Williams; Paula Kersten
Journal:  JMIR Mhealth Uhealth       Date:  2017-02-28       Impact factor: 4.773

8.  Protocol for a randomized, double blind, placebo controlled, crossover trial of Melatonin for treatment of Nocturia in adults with Multiple Sclerosis (MeNiMS).

Authors:  D Delgado; L Canham; N Cotterill; D Cottrell; M J Drake; K Inglis; D Owen; P White
Journal:  BMC Neurol       Date:  2017-03-27       Impact factor: 2.474

Review 9.  Emerging Approaches for Validating and Managing Multiple Sclerosis Relapse.

Authors:  Elizabeth A Mills; Ali Mirza; Yang Mao-Draayer
Journal:  Front Neurol       Date:  2017-03-29       Impact factor: 4.003

Review 10.  Western lifestyle and immunopathology of multiple sclerosis.

Authors:  Olga Matveeva; Jeroen F J Bogie; Jerome J A Hendriks; Ralf A Linker; Aiden Haghikia; Markus Kleinewietfeld
Journal:  Ann N Y Acad Sci       Date:  2018-01-27       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.